deltatrials
Completed INTERVENTIONAL NCT03536884

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE RADIANT)

A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Sponsor: UCB Biopharma SRL

Conditions Chronic Plaque Psoriasis Moderate to Severe Chronic Plaque Psoriasis
Interventions Bimekizumab Placebo Secukinumab
Updated 44 times since 2018 Last updated: Apr 2, 2026 Started: Jun 13, 2018 Primary completion: Sep 12, 2019 Completion: Aug 9, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis, this trial is completed. The trial is conducted by UCB Biopharma SRL and has accumulated 44 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

The study consists of a 48-week double-blind Treatment Period, an optional 96-week open-label extension (OLE) Period and an optional 48-week OLE2 Period for eligible subjects in the USA and Canada.

The study consists of a 48-week double-blind Treatment Period, an optional 96-week open-label extension (OLE) Period and an optional 48-week OLE2 Period for eligible subjects in the USA and Canada.

Status Flow

~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Feb 2025 · 4 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – ~Apr 2026 · 3 months · monthly snapshotApr 16, 2026 – present · 3 months · daily API

Change History

44 versions recorded

  1. Apr 16, 2026 — Present [daily]

    Completed

    Phase: PHASE3 → None

  2. Jan 2026 — Apr 2026 [monthly]

    Completed PHASE3

  3. Sep 2025 — Jan 2026 [monthly]

    Completed PHASE3

  4. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE3

  5. Oct 2024 — Feb 2025 [monthly]

    Completed PHASE3

▶ Show 39 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Aug 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE3

  7. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  8. Mar 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  10. Dec 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  11. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  12. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  13. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  14. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  15. Apr 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  16. Jan 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

  17. Oct 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE3

  18. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  19. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  20. Mar 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  21. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE3

  22. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  23. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  24. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  25. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  26. Mar 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  27. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  28. Nov 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  29. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  30. Jun 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  31. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  32. Jan 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  33. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  34. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  35. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  36. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  37. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  38. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  39. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).

Contact Information

Sponsor contact:
  • UCB Biopharma SRL
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Amsterdam, Netherlands , Augsburg, Germany , Barcelona, Spain , Berlin, Germany , Bexley, United States , Bialystok, Poland , Bialystok, Poland , Bialystok, Poland , Breda, Netherlands and 67 more locations